Business
Alphamab Oncology Appoints Mr. Fei Wang as Chief Financial Officer
Alphamab Oncology (stock code: 9966.HK) today announced the appointment of Mr. Fei Wang as Chief Financial Officer (CFO). Mr. Wang will be responsible for the company's capital operations, investment and financing management and investor relations, and report to Dr. Ting Xu, Chairman and CEO of Alphamab Oncology. Mr. Wang has accumulated over 20 years of professional experience in financial management and capital markets, with more than 15 years dedicated to the biopharmaceutical industry in Chi
About this update from Astrazeneca Plc
[{"type":"text","content":"SUZHOU, China, March 18, 2026 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) today announced the appointment of Mr. Fei Wang as Chief Financial Officer (CFO). Mr. Wang will be responsible for the company's capital operations, investment and financing management and investor relations, and report to Dr. Ting Xu, Chairman and CEO of Alphamab Oncology. Mr. Wang has accumulated over 20 years of professional experience in financial management and capital markets, with more than 15 years dedicated to the biopharmaceutical industry in China and overseas. Mr. Wang's joining will further enhance the company's core competitiveness in the capital markets, by improving capital operation efficiency, expanding financing channels and deepening investor relations, supporting the exploration and realization of the company's innovative value and delivering greater long-term value to shareholders.","length":916,"tagName":"p"},{"type":"text","content":"Prior to joining Alphamab Oncology, Mr. Wang served successively as CFO for China operations at AstraZeneca, Group CFO at 3S Bio Inc. and Managing Partner at Hangzhou Yingzhiqin Private Equity Fund. During his tenure, Mr. Wang achieved remarkable success and accumulated extensive practical experience in areas including domestic and international financing, strategic mergers and acquisitions, investor relations management, and integrated financial management system establishment and control. He holds an MBA jointly conferred by Shanghai Jiao Tong University and Euromed Marseille Ecole de Management (now known as KEDGE) and is a non-practicing member of the Chinese Institute of Certified Public Accountants (CICPA).","length":722,"tagName":"p"},{"type":"text","content":"Dr. Ting Xu, Chairman and CEO of Alphamab Oncology, commented, "We are very pleased to welcome Mr. Fei Wang to Alphamab Oncology. Mr. Wang brings deep professional expertise in financial management and capital operations, coupled with extensive experience in understanding both biopharmaceutical industry dynamics and capital market rules. We are entering a new era driven by differentiated innovation and guided by a global vision for resource integration and market expansion. Mr. Wang's appointment will enhance our capital allocation efficiency and further build a transparent and efficient communication br...